Stevens Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Stevens Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-15,778	Closed	-$1.34M	–	796
2018 Q4	$1.34M	Buy	+15,778	New	+$1.68M	0.07%	322
2018 Q3	–	Sell	-5,009	Closed	-$647K	–	857
2018 Q2	$647K	Buy	+5,009	New	+$559K	0.02%	500
2017 Q1	–	Sell	-11,596	Closed	-$735K	–	991
2016 Q4	$735K	Buy	+11,596	New	+$732K	0.03%	492
2015 Q1	–	Sell	-14,635	Closed	-$486K	–	1119
2014 Q4	$486K	Buy	14,635 +3,587	+32%	+$117K	0.02%	590
2014 Q3	$324K	Sell	11,048 -17,731	-62%	-$589K	0.01%	712
2014 Q2	$1.12M	Buy	28,779 +16,564	+136%	+$672K	0.03%	478
2014 Q1	$513K	Buy	+12,215	New	+$509K	0.01%	657

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Stevens Capital Management's LGND Position: Q1 2019 in Review

Stevens Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 15,778 shares — an estimated $1.34M sold.

Stevens Capital Management first reported a position in LGND in Q1 2014 and held it in 7 quarters. The position peaked at $1.34M in Q4 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

Stevens Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Stevens Capital Management sold 15,778 Ligand Pharmaceuticals shares in Q1 2019, an estimated $1.34M.
Stevens Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Stevens Capital Management's Ligand Pharmaceuticals position peaked at $1.34M in Q4 2018.
330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Stevens Capital Management's 13F filing for Q1 2019, filed 3 May 2019.